Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.
You may also be interested in...
DPP IV Inhibitor Januvia First Out Of The Gate
Merck’s type 2 diabetes treatment is approved a few weeks before the estimated user fee date of Novartis’ Galvus.
DPP IV Inhibitor Januvia First Out Of The Gate
Merck’s type 2 diabetes treatment is approved a few weeks before the estimated user fee date of Novartis’ Galvus.
Novartis Seeks European Approval For Galvus
The novel type 2 diabetes therapy has a likely November user fee date in the U.S.